News Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing Staff April 23, 2022 Iframe sync Post navigation Previous: The COVID-19 Respiratory Roundtable Issues Joint Letter Urging Canadians to Continue Protecting Each OtherNext: XVIVO Presents Interim Report January-March 2022 More Stories Diagnostics EHR Healthcare News Pharmaceutical Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope Staff January 11, 2026 Clinical Trial DNA News Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response Staff January 11, 2026 Cancer Clinical Trial Healthcare News Pharmaceutical Pregnancy Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand Staff January 11, 2026
